newsfilter
← Latest News
Business Wire·

Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum™

Company plans to conduct an additional clinical trial for potential resubmission of BLA Company expects to hold a Type C meeting with the FDA in early 2022 to discuss the clinical trial protocol Sesen Bio (NASDAQ:SESN), a late-stage clinical compa